- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about disease
Recent news which mentions disease
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
May 15, 2026
From Benzinga
From Benzinga
Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back
May 07, 2026
Tickers
RXRX
From Benzinga
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
May 04, 2026
From Benzinga
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million
July 09, 2025
From Benzinga
Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients
June 20, 2025
From Benzinga
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug
June 20, 2025
From Benzinga
From Benzinga
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
June 06, 2025
From Benzinga
From Benzinga
From Benzinga
Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?
May 23, 2025
From Benzinga
Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine
April 14, 2025
From Benzinga
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
April 10, 2025
From Benzinga
Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients
April 08, 2025
From Benzinga
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
April 02, 2025
From Benzinga
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
March 31, 2025
From Benzinga
Why Is Portage Biotech Stock Skyrocketing Friday?
March 28, 2025
From Benzinga
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors
March 26, 2025
From Benzinga
Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology
March 25, 2025
From Benzinga
Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough
March 20, 2025
Tickers
JNJ
From Benzinga
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial
March 19, 2025
Tickers
RGNX
From Benzinga
AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients
March 17, 2025
From Benzinga
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025
March 17, 2025
From Benzinga
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
March 17, 2025
From Benzinga
Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment
March 17, 2025
From Benzinga
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
March 13, 2025
From Benzinga
Cannabis Takes On Superbugs: Could This New Drug 'Change Infection Treatment Forever'?
February 05, 2025
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.